Use of the one-shot Johnson & Johnson Covid vaccine will resume within days, but with a warning added to its label about the risk for a rare blood-clotting disorder that has occurred among young women, the Food and Drug Administration announced on Friday.

Concerns about the disorder had led to a pause in the use of the vaccine that began 10 days earlier.

The F.D.A. decided against limiting the vaccine’s use by age or gender, although some European countries have imposed such restrictions on a vaccine made by AstraZeneca because of a similar clotting disorder.

Federal health officials said information about the disorder would also be provided at vaccination sites, and Dr. Peter Marks, the F.D.A.’s top vaccine regulator, predicted that the shots could be resumed by Saturday morning.